3.4 News

February 16, 2018

Tempus and the Parker Institute for Cancer Immunotherapy Work Together to Analyze Data to Help Inform Immunotherapy Treatments

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Parker Institute for Cancer Immunotherapy will work together to analyze clinical and molecular data to better determine which patients will have a positive res...

January 31, 2018

Precision Medicine World Conference

Eric Lefkofsky, founder and CEO of Tempus discusses the tools and approach necessary to usher in an era of personalized medicine.

January 25, 2018

Tempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer Patients

CHICAGO, Jan. 25, 2018 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced a collaboration with NYU School of Medicine aimed at improving outcomes for patients diagnosed with pancreatic cancer. Pa...

January 4, 2018

Tempus and Vanderbilt-Ingram Cancer Center Announce Data Initiative to Improve Outcomes for Cancer Patients

CHICAGO, Jan. 04, 2018 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients. As part of t...

December 21, 2017

CancerLinQ Engages Leading Technology Companies Tempus and Precision HealthAI to Accelerate Data-Driven Insights to Oncologists and the Cancer Care Community

Alexandria, Va.— CancerLinQ LLC and the data services companies Tempus and Precision HealthAI announced today they have entered into an agreement that will accelerate development and delivery of high-quality, de-identified clinical databases for use by CancerLinQ®, its oncologist subscribers, partners, and the broader cancer community. The agreement wil...

December 11, 2017

Tempus unveils a standalone tool for structuring clinical data at scale

Why do some patients respond to immuno-oncology drugs when others don’t? It’s one of many million-dollar questions in medicine that confound companies, researchers, and clinicians alike. And the really frustrating part? We know where many of the answers lie. They’re trapped in electroni...

December 7, 2017

Tempus Unveils Tempus O, a Platform to Structure and Annotate Clinical Data at Scale

CHICAGO, Dec. 07, 2017 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data today announced the launch of Tempus O, a groundbreaking system that collects, structures and analyzes clinical data from electronic medica...

November 15, 2017

Tempus Announces Latest Immunotherapy Project

CHICAGO, Nov. 15, 2017 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, along with Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center at Hackensack Meridian HealthHackensac...

November 10, 2017

COMPUTING CARE

BY ERIN MCCALLISTER, SENIOR EDITOR Tempus Labs Inc. has created a machine learning tool that can help physicians make better treatment decisions by comparing a cancer patient’s genetic and clinical profile to those of thousands of other patients with known treatment outcomes. The tool supple...

November 8, 2017

Enlisting technology in the war against cancer

Eric Lefkofsky, founder and CEO at Tempus participates in keynote conversation with Carleen Hawn, CEO of Healthspottr focused on enlisting technology in the war against cancer.

Show More